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THE FUTURE OF DIRECT-TO-CONSUMER GENETIC TESTING: 
REGULATION AND INNOVATION 
 
Chelsea Weiermiller* 
 
Direct-to-consumer (“DTC”) genetic testing companies face 
regulation from numerous parties. The Food and Drug 
Administration has taken the lead role in the regulation of this 
industry. The Federal Trade Commission must make sure that 
consumers are not misled by unscrupulous marketing and false 
advertising. The Centers for Medicare and Medicaid Services 
under the Clinical Laboratory Improvement Amendments should 
ensure that genetic tests are analytically and clinically valid. State 
laws and federal statutes like the Genetic Information 
Discrimination Act address consumer privacy concerns. The recent 
Molecular Pathology v. Myriad Genetics, Inc. Supreme Court 
decision will shape the direction of DTC genetic testing patents. 
Case law is also influencing DTC genetic consumer protection. 
These various regulatory mechanisms must strike a balance 
between protecting DTC genetic test consumers without stifling 
important innovations in this industry.  
I.  INTRODUCTION 
Imagine the possibility of medical treatments tailored to your 
DNA. Although personalized medicine might be a long way off,1 a 
simple medical test taken in the privacy of your home could tell 
                                                        
* J.D. Candidate, University of North Carolina School of Law, 2016. The 
author would like to thank Meredith Corley for inspiring her topic selection. The 
author would also like to thank the NC JOLT staff and editors for their patience 
and guidance–especially Matt Spangler, Nic Turza, Kelly Morris, Kyle Evans, 
and Ben Szany.  
1 See Press Release, Am. Chem. Soc’y, Personalized Medicine Has Finally 
Arrived – or Has It? (Feb. 26, 2014) available at http://www.acs.org/content/ 
acs/en/pressroom/presspacs/2014/acs-presspac-february-26-2014/personalized-
medicine-has-finally-arrived-or-has-it.html.  
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you the likelihood of contracting a specific disease. 2  Genetic 
testing can identify changes in your gene expression3 to determine 
your risk of developing a genetic disorder, or serve to confirm the 
existence of a genetic condition.4 Some companies market genetic 
tests directly to consumers. 5  These companies have provided 
consumers with access to genetic information without involving 
doctors or insurance companies in the process.6  
Direct-to-Consumers (“DTC”) genetic tests have generated a 
great deal of controversy. 7  Since the Human Genome Project 
concluded in April 2003, 8  DNA sequencing has become 
exponentially faster and much more affordable.9 In the late 2000’s, 
several companies emerged to take advantage of the burgeoning 
consumer demand for genetic information via the Internet.10 Rather 
                                                        
2 See Direct to Consumer Genetic Tests, U.S. FTC (Jan. 2014), http://www. 
consumer.ftc.gov/articles/0166-direct-consumer-genetic-tests.  
3  The epigenome consists of chemical compounds from things like food, 
medicine, or pesticides that mark and change the genome over time. Epigenetics 
might help explain differences between identical twins. Although twins might 
have almost the exact same genome and DNA, one identical twin could develop 
arthritis, for example, due to environmental changes over the course of his or her 
lifetime. Epigenomics, NAT’L HUMAN GENOME RESEARCH INST. (May 7, 2012), 
http://www.genome.gov/27532724. 
4  What is Genetic Testing?, GENETICS HOME REFERENCE (Nov. 4, 2014), 
http://ghr.nlm.nih.gov/handbook/testing/genetictesting.  
5 See Pascal Su, Direct-to-Consumer Genetic Testing: A Comprehensive View, 
86 YALE J. BIOL. MED. 359, 359 (2013).   
6 What is Direct-to-Consumer Genetic Testing?, GENETICS HOME REFERENCE 
(Nov. 4, 2014), http://ghr.nlm.nih.gov/handbook/testing/directtoconsumer.  
7  James P. Evans & Robert C. Green, Commentary, Direct to Consumer 
Genetic Testing: Avoiding a Culture War, 11 GENETICS IN MED. 568, 568 (2009). 
8 All about the Human Genome Project (HGP), NAT’L HUMAN GENOME 
RESEARCH INST., http://www.genome.gov/10001772 (last updated Mar. 18, 2014).  
9 The Human Genome Project cost $1 billion and 8 years to complete. As of 
2013, Eric D. Green, the director of the National Human Genome Research 
Institute, estimated it would take several days and as little as $4000–$5000 to 
sequence an entire human genome. Gina Kolata, Human Genome, Then and 
Now, N.Y. TIMES (Apr. 15, 2013), http://www.nytimes.com/2013/04/16/science/ 
the-human-genome-project-then-and-now.html?_r=0.   
10 In 2011, the Genetics and Public Policy Center released an updated list of 
twenty Direct-to-Consumer Genetic Testing companies, including: 23andMe, 
Advanced Healthcare, Inc., deCODE Genetics, Holistic Health, and Map My 
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than sequencing the entire human genome as the Human Genome 
Project did, these companies examined single nucleotide 
polymorphisms11 (“SNPs”)—DNA sequences in the genome that 
usually differ between individuals.12 SNP tests analyze a person’s 
ancestry and health, as well as a number of other traits.13 Generally, 
DTC genetic testing companies advertise and operate online. 14 
Although the specifics between DTC genetic testing companies 
may vary, generally a consumer purchases the product online, and 
then receives a test kit in the mail.15 Next, the consumer performs a 
cheek swab or obtains a saliva sample.16 The consumer then sends 
the test kit back to the genetic testing company where it is analyzed 
by a lab.17 The consumer receives the results either online or by 
mail.18  
In 2010, about 30 companies offered more than 400 different 
DTC genetic tests.19 However, due to increased state and federal 
                                                                                                                            
Gene, among others. See GENETICS & PUB. POLICY CTR., GPPC RELEASES 
UPDATED LIST OF DTC GENETIC TESTING COMPANIES (2012), available at 
http://www.dnapolicy.org/resources/DTCTableAug2011Alphabydisease.pdf.   
11  SNPs occur throughout a person’s DNA, sometimes acting as genetic 
markers. Although most SNPs do not have any effect on human health and 
development, researchers have found that some SNPs can predict drug responses 
and track inheritance of disease genes. There are about 10 million SNPs in the 
human genome, occurring once every 300 nucleotides. What are Single 
Nucleotide Polymorphisms (SNPs)?, GENETICS HOME REFERENCE (Nov. 4, 
2014), http://ghr.nlm.nih.gov/handbook/genomicresearch/snp. 
12 Direct-to-Consumer Genetic Testing, PERS. GENETICS EDUC. PROJECT, 
http://www.pged.org/direct-to-consumer-genetic-testing (last visited Oct. 20, 
2014).  
13 DTC genetic testing companies report traits ranging from “a person’s ability 
to taste bitter flavors or the photic sneeze reflex (uncontrollable sneezing when 
exposed to bright light) to risk for developing heart disease or diabetes.” Id.  
14 Kayte Spector-Bagdady & Elizabeth Pike, Consuming Genomics: Regulating 
Direct-to-Consumer Genetic and Genomic Information, 92 NEB. L. REV. 677, 
689 (2014). 
15 Id.  
16 Id.  
17 Id.  
18 Id.  
19 Arthur L. Beaudet & Gail Javitt, Which Way For Genetic-Test Regulation?, 
466 NATURE 816, 817 (2010).  
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regulation, many DTC genetic testing companies have 
discontinued selling their health-related products.20 
On November 22, 2013, 23andMe Inc.—the last major DTC 
genetic testing company offering health-related genetic test 
services—received a formal warning letter from the Food and 
Drug Administration (“FDA”) forcing the company to cease 
marketing its health-related Personal Genome Service.21 The FDA 
warned that 23andMe was selling its Personal Genome Service 
“without marketing clearance or approval in violation of the 
Federal Food Drug and Cosmetic Act.” 22  The FDA seemed 
especially frustrated that 23andMe stopped communicating with 
the agency in May 2013 while initiating new marketing strategies 
including televised commercials for the Personal Genome 
Service.23 
Despite the agency’s harsh rebuke, as of June 20, 2014, 
23andMe is again in talks with the FDA to gain preliminary 
approval24 for its test for Bloom syndrome, a rare genetic disorder 
                                                        
20 Spector-Bagdady & Pike, supra note 14, at 680. The FDA started to enforce 
against DTC genetic testing companies in May 2010, after Pathway Genomics 
announced plans to start selling its home use saliva kit at more than 6000 
Walgreens Stores, making the product the company had been selling online for 
years much more accessible to consumers. The FDA was concerned about the 
health-related claims the company was making, and announced its concern that 
the company was marketing an unapproved medical device. The FDA sent out 
five additional letters to genetic testing companies (23andMe, Knome, 
Navigenics, deCODE Genetics and Illumina) in June 2010, and fourteen more in 
July 2010 to companies that appeared to be marketing FDA defined medical 
devices without clearance. Id. at 706–08.  
21  Letter from Alberto Gutierrez, Dir. Office of In Vitro Diagnostics and 
Radiological Health, Ctr. For Devices and Radiological Health, Food and Drug 
Admin., U.S. Dep’t. of Health and Human Servs., to Anne Wojcicki, C.E.O., 23 
and Me, Inc. (Nov. 22, 2013), http://www.fda.gov/iceci/enforcementactions/ 
warningletters/2013/ucm376296.htm [hereinafter Warning Letter to Wojcicki]. 
22 Id.  
23 See id.  
24 According to the FDA’s website, a 510(k) application is required for premarket 
approval for a new medical device to demonstrate that the device is at least as 
safe and effective as a legally marketed device. 510(k) Clearances, U.S. FOOD AND 
DRUG ADMIN., http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ 
DeviceApprovalsandClearances/510kClearances/ (last updated June 6, 2014).  
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involving a single mutation to one gene.25 If 23andMe’s 510(k) 
application for Bloom syndrome is successful, the submission will 
help establish parameters for future genetic test submissions, and 
will serve to assure DTC genetic testing consumers that the tests 
are valid.26  
This Recent Development argues that the Federal Trade 
Commission (“FTC”), FDA, Centers for Medicare and Medicaid 
Services (“CMS”), and other federal regulatory agencies should 
enforce regulations against DTC genetic testing companies making 
dubious scientific claims, but exercise enforcement discretion 
against companies that demonstrate robust scientific findings in 
order to make these DTC genetic tests safe for consumers without 
stifling important innovations. Part II examines the current 
regulatory status of the DTC genetic testing industry and analyzes 
the role of the various stakeholders in the ongoing efforts to 
regulate this industry. Part III considers the implications of the 
latest developments in the DTC genetic testing industry in a case 
study of one DTC genetic testing company, Interleukin Genetics. 
This Recent Development argues for more coordinated regulation 
of the DTC genetic testing industry because concerns of consumer 
autonomy and industry innovation outweigh the potential harm of 
most of these tests. 
II.  THE CURRENT REGULATORY STATUS: INSTITUTIONAL 
PERSPECTIVES 
Various institutions regulate the DTC genetic testing 
companies, and several federal agencies will likely play oversight 
roles. These agencies include the FDA, CMS under the Clinical 
Laboratory Improvement Amendments (“CLIA”), the FTC, and 
the Equal Opportunity Employment Commission (“EEOC”) under 
the Genetic Information Nondiscrimination Act (“GINA”). States 
also play an important part in the regulation of this industry. 
                                                        
25 Update on the Regulatory Review Process with the FDA, 23ANDME BLOG 
(June 20, 2014), http://blog.23andme.com/news/update-on-the-regulatory-review- 
process-with-the-fda/.  
26 See id.  
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Finally, this part considers important case law affecting the DTC 
industry. 
A. Food and Drug Administration: Regulation of the DTC Industry  
The FDA leads the regulation of the DTC genetic testing 
industry.27 The FDA derives its authority to regulate the sale and 
distribution of medical devices from the Food Drug and Cosmetic 
Act.28 Genetic tests, as a category of in vitro diagnostic (“IVD”) 
devices,29 generally fall under the definition of medical device30 
and are therefore subject to regulation by the FDA.31 IVD refers to 
                                                        
27  See Direct to Consumer Genetic Testing and the Consequences to the 
Public: Hearing Before the Subcomm. on Oversight and Investigations of the H. 
Comm. on Energy and Commerce, 111th Cong. (2010) (statement of Jeffrey 
Shuren, M.D., Dir. For Devices and Radiological Health, Food & Drug Admin., 
Dep’t. of Health and Human Serv’s.), available at http://www.fda.gov/ 
NewsEvents/Testimony/ucm219925.htm [hereinafter Shuren—Statement]. 
28 Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 301–399f (2006).   
29 In Vitro Diagnostic Products for Human Use, 21 C.F.R. § 809.3(a) (2013) 
(“[I]n vitro diagnostic products are those reagents, instruments, and systems 
intended for use in the diagnosis of disease or other conditions, including a 
determination of the state of health, in order to cure, mitigate, treat, or prevent 
disease or its sequelae. Such products are intended for use in the collection, 
preparation, and examination of specimens taken from the human body. These 
products are devices as defined in section 201(h) of the Federal Food, Drug, and 
Cosmetic Act (the act), and may also be biological products subject to section 
351 of the Public Health Service Act.”).   
30 Medical device is defined as: 
an instrument, apparatus, implement, machine, contrivance, implant, in 
vitro reagent, or other similar or related article, including any component 
part, or accessory that is intended for use in the diagnosis of disease or other 
conditions, or in the cure, mitigation, treatment, or prevention of disease, in 
man or other animals, or is intended to affect the structure or function of the 
body of man or other animals. 
21 U.S.C § 321(h) (2013). 
31  AMANDA K. SARATA & JUDITH A. JOHNSON, CONG. RESEARCH SERV., 
R43438, REGULATION OF CLINICAL TESTS: IN VITRO DIAGNOSTIC (IVD) 
DEVICES, LAB. DEV.TESTS (LDTS), AND GENETIC TESTS 1 (2014). But see 
Michael Eisen, FDA vs. 23andMe: How Do We Want Genetic Testing to be 
Regulated?, IT IS NOT JUNK (Nov. 26, 2013), http://www.michaeleisen.org/ 
blog/?p=1480 (arguing that the FDA’s definition of a medical device is too 
broad to be useful in the case of DTC genetic testing as genetic tests “are closer 
to a family history than an accurate diagnostic”). 
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a method of performing a diagnostic test outside of the living body 
in an artificial environment, usually in a laboratory.32 IVDs differ 
from other medical devices because a false positive or false 
negative result could potentially harm a patient.33  
Between 200734 and 2010, the FDA did not take a substantial 
role in regulating DTC genetic testing companies.35 However, by 
2010, the FDA stated that it had reconsidered its position regarding 
the non-enforcement of these tests because the tests put the patients 
at risk for incorrect diagnosis and treatment.36 On July 22, 2010, 
Jeffrey Shuren, the Director for Devices and Radiological Health 
for the FDA, testified before the U.S. House of Representatives, 
explaining that the DTC companies had recently begun “aggressively 
market[ing]” to consumers.37 The FDA was particularly concerned 
that one company, Pathway Genomics, was planning to sell its 
DTC genetic testing product on 6,000 Walgreen’s store shelves, 
making their product much more accessible to the average 
consumer. 38  Additionally, Shuren pointed out that 23andMe’s 
product was accessible to consumers on Amazon.com. 39  Shuren 
commented that although many genetic tests were approved after 
2003, none of the DTC genetic tests currently on the market had 
undergone FDA premarket approval to “ensure that the test results 
being provided to patients are accurate, reliable, and clinically 
meaningful.” 40  FDA decided to strictly regulate DTC genetic 
                                                        
32 In vitro diagnostic comes from the Latin “within the glass.” IVDs vary 
widely—from pregnancy tests to cervical cancer screening tests. IVDs contrast 
with other medical technologies because these tests never directly interact with 
the human body, but rather derive their use value from the health information 
they can provide to a patient. About In Vitro Diagnostics, EUROPEAN 
DIAGNOSTIC MFRS. ASS’N, http://www.edma-ivd.be/index.php?page=About-In-
Vitro-Diagnostics (last visited November 1, 2014). 
33 See SARATA & JOHNSON, supra note 31, at 1. 
34 The first DTC companies 23andMe and deCODEme launched in 2007. 
Spector-Bagdady & Pike, supra note 14, at 688. 
35 See SARATA & JOHNSON, supra note 31, at 1. 
36 Spector-Bagdady & Pike, supra note 14, at 703–04. 
37 Shuren—Statement, supra note 27. 
38 Id.  
39 Id.  
40 Id.  
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testing companies because these companies were assessing 
high-risk diseases, and many of these test manufacturers were 
corporations rather than hospitals or public laboratories that the 
FDA originally wanted to exempt from regulation.41  
Laboratory Developed Tests42 (“LDTs”) are a specific type of 
IVD that are designed for clinical use and are manufactured in a 
single laboratory.43 Some DTC genetic testing companies conducting 
their own analysis and using their own genetic data offer LDTs.44 
Traditionally, the FDA exercised discretion not to enforce against 
LDTs because these types of tests were relatively simple.45 However, 
in recent years, the FDA has noted that these types of tests have 
become increasingly complex and “almost indistinguishable” from 
other IVDs.46 On July 31, 2014, in a major shift, the FDA issued 
new regulatory draft guidance for LDTs “based on risk to patients 
rather than whether they were made by a conventional manufacturer 
or a single laboratory.” 47  The regulatory guidance imposes the 
strictest guidelines for the highest risk LDTs, and recommends 
enforcement discretion for lower risk LDTs and LDTs for rare 
diseases, among others.48 The FDA is currently seeking feedback 
to determine what constitutes a rare disease, and whether the 
enforcement discretion should be limited to tests that are designed, 
manufactured, and used within a single laboratory.49  
The FDA’s planned discretion not to enforce for rare diseases 
might have influenced 23andMe’s decision to submit their 510(k) 
                                                        
41 Spector-Bagdady & Pike, supra note 14, at 702.  
42 Laboratory Developed Tests, U.S. FOOD AND DRUG ADMIN., http://www. 
fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/uc
m407296.htm (last updated Oct. 3, 2014).  
43 “Single laboratory” refers to a facility with a single CLIA certificate as 
described in 42 C.F.R. § 493.43(a)–(b). 
44 Spector-Bagdady & Pike, supra note 14, at 703.  
45 U.S. FOOD AND DRUG ADMIN., supra note 42.  
46 Alexander Gaffney, In Major Shift, the FDA to Regulate Lab-Developed 
Tests as Normal Devices, REGULATORY AFFAIRS PROF’LS SOC’Y (Aug. 1 2014), 
http://www.raps.org/Regulatory-Focus/News/2014/08/01/19934/In-Major-Shift-
FDA-to-Regulate-Lab-Developed-Tests-as-Normal-Devices/. 
47 U.S. FOOD AND DRUG ADMIN., supra note 42.  
48 Id.  
49 Id.  
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application for Bloom syndrome.50 Although some have heralded 
this submission as the first step in getting hundreds of its tests 
approved,51 many of 23andMe’s tests are for much more complex 
diseases, which might not necessarily fit the FDA’s definition of a 
“rare disease” subject to planned LDT enforcement discretion.52 
Anne Wojcicki, CEO of 23andMe, has commented that their tests 
are difficult to regulate on a case-by-case basis because the 
company does not just offer “a single type of test.”53  
While the new regulatory guidance will be phased in over the 
next decade or so, politicians, doctors’ groups, and industry leaders 
have already reacted negatively to these proposed regulations.54 
For example, the American Medical Association, a powerful 
lobbying group for doctors,55 and the Association for Molecular 
Pathology, an association representing molecular testing 
companies,56 have expressed concern about the new framework. 
                                                        
50  “Bloom syndrome is a very rare disorder in most populations, and its 
overall frequency is unknown. The disorder is more common in people of Central 
and Eastern European (Ashkenazi) Jewish background, among whom about 1 in 
50,000 are affected. Approximately one-third of people with Bloom syndrome 
are of Ashkenazi Jewish descent.” Bloom Syndrome, GENETIC HOME REFERENCE, 
http://ghr.nlm.nih.gov/condition/bloom-syndrome (last updated Nov. 2010).  
51 Robert Hof, Seven Months After FDA Slapdown, 23andMe Returns with 
New Health Report Submission, FORBES (June 20, 2014, 12:04 PM), http:// 
www.forbes.com/sites/roberthof/2014/06/20/seven-months-after-fda-slapdown-
23andme-returns-with-new-health-report-submission/. 
52 For example, nearly 5 million people live with Alzheimer’s disease. Alzheimer’s 
Facts and Figures, ALZHEIMER’S ASS’N, http://www.alz.org/alzheimers_disease_ 
facts_and_figures.asp (last visited Oct. 21, 2014). 
53 Robert Hof, ‘We Are Going For Change’: A Conversation with 23andMe 
CEO Anne Wojcicki, FORBES (Aug. 15, 2014, 10:50 AM), http://www.forbes.com/ 
sites/roberthof/2014/08/15/we-are-going-for-change-a-conversation-with-23andme- 
ceo-anne-wojcicki/.  
54 Gaffney, supra note 46.  
55 Barbara L. McAneny, MD, Chair of the Board, Am. Med. Assoc., AMA 
Statement on FDA Proposal Regarding Diagnostic Testing, AM. MED. ASS’N 
(Aug. 1, 2014), http://www.ama-assn.org/ama/pub/news/news/2014/2014-08-01- 
fda-proposal-diagnostic-testing.page. 
56 The Association for Molecular Pathology Voices Concern with U.S. FDA 
Anticipated Details of Laboratory Developed Test Draft Guidance, ASS’N FOR 
MOLECULAR PATHOLOGY, http://www.businesswire.com/news/home/20140731006689/ 
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However, AdvaMed, the medical device’s largest trade association, 
expressed support for the new regulation, indicating that the 
guidance would create parity between currently regulated devices 
and unregulated LDTs.57 The new guidance could ultimately affect 
up to 11,000 of these DTC genetic tests in up to 2,000 different 
laboratories.58  
B. Centers for Medicare and Medicaid Services and the Clinical 
Laboratory Improvement Act: More Stringent Requirements 
Necessary  
CMS is another important player in the regulation of the DTC 
genetic testing industry. CMS regulates the DTC genetic testing 
industry under the Clinical Laboratory Improvement Amendments 
Act of 1988 (“CLIA”) 59  Under CLIA, CMS sets standards for 
laboratories that provide information about health-related 
conditions. 60  However, there are no special requirements for 
laboratories performing genetic tests under CLIA.61  
Clinical genetic tests are typically evaluated using the ACCE 
framework, which includes testing for “analytical validity, clinical 
validity, clinical utility, and ethical, social and legal 
implications.” 62  Although CLIA assures that genetic tests are 
                                                                                                                            
en/Association-Molecular-Pathology-Voices-Concern-U.S.-FDA (last updated July 
31, 2014 8:37 PM). 
57 AdvaMedDx Commends FDA's Issuance of LDT Draft Framework, ADV. 
MED. TECH. ASS’N (July 31, 2014), http://advamed.org/news/117/advameddx-
commends-fdas-issuance-of-ldt-draft-framework. 
58 Matthew Harper, FDA To Regulate Thousands Of Cancer, Genetic, And 
Other Diagnostics, FORBES, http://www.forbes.com/sites/matthewherper/2014/07/31/ 
fda-to-regulate-thousands-of-cancer-genetic-and-other-diagnostics/ (last updated 
July 31, 2014, 1:03 PM).  
59 42 C.F.R. § 493.1253 (2003).  
60 Kathryn Schleckser, Physician Participation in Direct-to-Consumer Genetic 
Testing: Pragmatism or Paternalism?, 26 HARV. J.L. & TECH. 695, 707 (2013).  
61 See Genetic Testing: Understanding Your Genes and What They Mean for 
Your Health, GENETIC ALLIANCE, http://www.geneticalliance.org/advocacy/ 
policyissues/genetictesting (last visited Oct. 20, 2014).   
62 The ACCE takes its name from the four main criteria for evaluating a 
genetic test. ACCE Model Process for Evaluating Genetic Tests, CTRS. FOR DISEASE 
CONTROL AND PREVENTION, http://www.cdc.gov/genomics/gtesting/ACCE/ (last 
updated Jan. 3, 2010). 
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analytically valid (“how well a test recognizes a genetic variant”), 
CLIA does not ensure clinical validity (“the association of the 
variant with a disease or medical condition”) or clinical utility 
(“whether the information of the disease or medical condition can 
be of clinical use to a consumer”) of the genetic medical 
information.63 Therefore, it is possible that a test could satisfy the 
highest analytical standard, but still be inaccurate if there is not a 
strong relationship between the genetic variant and the clinical 
manifestation of disease.64  
In addition, while it is widely recognized that genetic testing is 
very complex, there are no proficiency standards for a genetic 
testing subspecialty. 65  Because specific proficiency testing for 
these genetic tests is not mandated under CLIA, laboratories 
determine their own competencies.66  
Even if the FDA restricts access to DTC genetic tests, CMS 
needs to assure the quality of these tests.67 The government must 
correct the systemic gaps in oversight that make consumers 
vulnerable to inaccurate results. 68 For example, the Government 
Accountability Office (“GAO”) has criticized CMS’s oversight of 
CLIA laboratories, finding in 2006 that “CMS failed to sanction 
labs with ‘serious, condition-level deficiencies on consecutive 
surveys.’”69 CLIA theoretically requires laboratories to ensure the 
validity of all tests performed, but as previous GAO reports have 
                                                        
63 Spector-Bagdady & Pike, supra note 14, at 719.   
64 Id. at 721.   
65 Id.  
66 Gail H. Javitt & Kathy Hudson, Federal Neglect: Regulation of Genetic 
Testing, ISSUES IN SCI. & TECH. (Nov. 27, 2013), http://issues.org/22-3/javitt/. 
67 See id.  
68 Id.  
69 Jessica Elizabeth Palmer, Genetic Gatekeepers: Regulating Direct-to-Consumer 
Genomic Services in an Era of Participatory Medicine, 67 FOOD & DRUG L.J. 
475, 503 (2012) (citing US GOV’T ACCOUNTABILITY OFFICE, GAO-06-416, 
CLINICAL LAB QUALITY: CMS AND SURVEY ORGANIZATION OVERSIGHT 
SHOULD BE STRENGTHENED, 8 (2006)) (“CMS’s oversight of clinical lab quality 
is inadequate to ensure that labs are meeting CLIA requirements.”).  
16 N.C. J.L. & TECH. ON. 138, 148 
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found,70 CMS could do much more to “ensure that their test results 
are accurate, reliable, timely, and confidential and do not present 
the risk of harm to patients.”71 CMS should do more to make sure 
that consumers are getting analytically valid and clinically valid 
test results. 
C.  Federal Trade Commission and the Prevention of Misleading 
DTC Genetic Test Marketing 
The FTC has broad investigative and enforcement authority to 
protect consumers from unfair and deceptive trade practices under 
the Federal Trade Commission Act. 72  In 2014, the FTC started 
regulating DTC genetic testing companies for the first time, 
indicating that the agency plans to play a bigger role in protecting 
consumers of DTC genetic tests. 73  For example, the FTC filed 
charges against Genelink, Inc in January and L’Oréal USA Inc. in 
June for offering purported personalized genetics testing services.74  
Genelink and its subsidiary foru™ made claims that its 
nutritional products could help compensate for “disadvantaged” 
genes.75 The FTC charged that Genelink and foru™ engaged in 
unfair and deceptive trade practices, and made misleading 
advertisements in violation of sections 5(a) and 12 of the FTC 
Act.76 The FTC wanted to prevent these companies from making 
                                                        
70 US GOV’T ACCOUNTABILITY OFFICE, GAO-06-416, CLINICAL LAB QUALITY: 
CMS AND SURVEY ORGANIZATION OVERSIGHT SHOULD BE STRENGTHENED, 8 
(2006), available at http://www.gao.gov/assets/260/250504.pdf. 
71 42 C.F.R. § 493.1253(b)(2)(vii) (2013).  
72 See 15 U.S.C. § 45(a)(1) (2013).  
73 Jennifer K. Wagner, FTC Takes Action to Protect Consumers from False Genetic 
Advertising Claims, GENOMICS LAW REPORT, http://www.genomicslawreport.com/ 
index.php/2014/07/03/ftc-takes-action-to-protect-consumers-from-false-genetic-
advertising-claims/#more-13323 (last updated July 3, 2014).  
74 Id.  
75 Complaint at 1, In re GeneLink, Inc. & Foru Int’l Corp., No. 112-3095 
(F.T.C. Jan. 7, 2014). 
76 Id. On May 8, 2014, the Commission voted 3-1 to approve the final orders 
against the companies. Wagner, supra note 73.  
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health-related genetic claims “unless the claim is true and 
supported by at least two adequate and well-controlled studies.”77  
The Council for Responsible Nutrition raised concerns in 
public comment that requiring two studies would become a 
“de-facto standard,” and that this type of testing by respondents 
would create an “undue burden.” 78  Furthermore, the Natural 
Products Association asserted, “If the FTC intends to depart from 
its traditional competent and reliable scientific evidence standard, 
then new formal guidance is necessary.”79 The FTC rejected the 
concerns in each of these public comments, clarifying that “[t]he 
optimal amount and type of evidence to substantiate a future claim 
will vary from case to case.”80 
In the L’Oréal decision and order, the Commission did not 
mandate that the company have two random clinical trials to 
substantiate its claims for its Lancôme Génifique and L’Oréal Paris 
Youth Code skincare products.81 Rather, the FTC indicated that 
L’Oréal must have “competent and reliable scientific evidence”82 
                                                        
77 Order at 4, In re GeneLink, Inc. & Foru Int’l Corp., No. 112-3095 (F.T.C. 
May 8, 2014). Well controlled studies are defined in the consent order as:  
[A] human clinical study that: is randomized and adequately controlled; 
utilizes valid end points generally recognized by experts in the relevant 
disease field; yields statistically significant between-group results; and is 
conducted by persons qualified by training and experience to conduct such 
a study. Such study shall be double-blind and placebo-controlled . . . . 
Id. at 2.  
78  Letter from Donald S. Clark, Sec’y, Fed. Trade Comm’n, to Rend 
Al-Mondhiry, Esq., Regulatory Counsel, Council For Responsible Nutrition 
(May 8, 2014) available at http://www.ftc.gov/system/files/documents/cases/ 
140512genelinkcouncilletter_0.pdf.   
79 Letter from Donald S. Clark, Re: Genelink, Inc., & Foru™ Int’l Corp FTC 
File No. 112-3095 and Docket Nos. C-4456 and C-4457 (May 8, 2014), available at 
http://www.ftc.gov/system/files/documents/cases/140512genelinknaturalletter_0.pdf. 
80 Joshua D. Wright, Statement of Comm’r Joshua D. Wright, FED. TRADE 
COMM’N (Jan. 7, 2014), available at http://www.ftc.gov/system/files/documents/ 
public_statements/567801/140107genelinkstatement.pdf.  
81 Order at 1, In re L’Oréal USA, Inc., No. 122-3016 (F.T.C. Sept. 24, 2014).  
82 Id. at 2. “Competent and reliable scientific evidence shall mean evidence, 
consisting of tests, analyses, research, or studies that have been conducted and 
evaluated in an objective manner by qualified persons and are generally 
accepted in the profession to yield accurate and reliable results.” Id.   
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before claiming that any of its products can affect gene activity or 
growth.83   
The FTC clarified three main takeaways from the L’Oréal 
decision.84 First, when advertisers claim that “studies show,” or 
“doctors recommend,” advertisers must have at least the level of 
substantiation purported in the advertisement.85 Second, the support 
for the product must be “fit to be tried.”86 Third, “once companies 
make objective product representations, long standing substantiation 
principles apply.”87 These principles apply to other DTC genetic 
testing companies claiming that their products affect genes.  
D.  Genetic Information Nondiscrimination Act  
The Genetic Information Nondiscrimination Act (“GINA”) 88 
prevents employers and health insurance companies from 
discriminating based on genetic information. 89  This act offers 
protection to consumers from the unauthorized use of their DTC 
genetic test results.90 
In 2013, the Equal Opportunity Employment Commission 
(“EEOC”) settled its first lawsuit alleging violations of the Genetic 
Information Nondiscrimination Act. 91  The EEOC found that 
Fabricut, Inc. (“Fabricut”), one of the world’s largest distributors 
of decorative fabrics, violated GINA when it requested prohibited 
                                                        
83 Id. at 3.  
84 Lesley Fair, FTC to L’Oreal: Scientific Claims Need Proof that’s More than 
Just Skin Deep, BUS. CTR. BLOG, http://business.ftc.gov/blog/2014/06/ftc-loreal-
scientific-claims-need-proof-thats-more-just-skin-deep (last updated June 30, 2014).  
85 Id.  
86 Id.  
87 Id.  
88 Genetic Information Nondiscrimination Act of 2008, Pub. L. No. 110-233, 
122 Stat. 881 (2008). 
89 Genetic Testing, GENETICS HOME REFERENCE, http://ghr.nlm.nih.gov/handbook/ 
testing?show=all#genetictesting (last updated Nov. 11, 2014) (explaining that 
Title I prevents genetic discrimination in health insurance, and Title II prevents 
genetic discrimination by employers).  
90 Su, supra note 5, at 361.  
91 Fabricut to Pay $50,000 to Settle EEOC Disability and Genetic Information 
Discrimination Lawsuit, U.S. EQUAL EMP’T OPPORTUNITY COMM’N, http:// 
www.eeoc.gov/eeoc/newsroom/release/5-7-13b.cfm (last updated May 7, 2013).  
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family medical history in its post-offer medical examination.92 On 
May 7, 2013 Fabricut agreed to pay $50,000 and to take action to 
prevent future discrimination.93  
Barbara Seely, EEOC Regional Attorney, noted that many 
employers still do not understand that requesting family medical 
history is prohibited.94 Additionally, according to a 2010 study, less 
than 20% of the adult population in Connecticut, Michigan, Ohio 
and Oregon had knowledge of genetic non-discrimination laws, 
while 80% perceived that these laws were very or somewhat 
important. 95  Over two-thirds were concerned with insurance 
companies using genetic test results to determine life insurance 
coverage and costs. 96  This study suggests that further public 
education is necessary to raise awareness of the protections 
provided by current genetic nondiscrimination laws.97 
While GINA creates additional safeguards through genetic 
nondiscrimination by health insurance companies and by 
employers, GINA is silent on a number of issues.98 For example, 
GINA does not bar genetic discrimination outside the health 
insurance and employment contexts, and does not address concerns 
                                                        
92 Id. Fabricut required Rhonda Jones to fill out a questionnaire and disclose 
separately listed disorders in her family medical history. Although Jones 
indicated in the questionnaire that she did not have Carpal Tunnel Syndrome 
(CTS), Fabricut required her to submit to further testing. Fabricut’s contract 
medical examiner, Knox Laboratories, found that Jones did have CTS, and 
Fabricut rescinded her application. The EEOC found that Fabricut engaged in 
illegal conduct when it discriminated against Jones based on genetic 
information–which includes family medical history. Id.  
93 Id.  
94 Id.  
95Alicia A. Parkman et. al., Public Awareness of Genetic Nondiscrimination 
Laws in Four States and Perceived Importance of Life Insurance Protections, J. 
GENETIC COUNSELING 1, 4–6 (2014), available at http://www.ncbi.nlm.nih.gov/ 
pubmed/25242499.  
96 Id.  
97 Id. at 7.  
98 Colin McFerrin, DNA, Genetic Material, and A Look at Property Rights: 
Why You May Be Your Brother's Keeper, 19 TEX. WESLEYAN L. REV. 967, 984 
(2013) (citing Elizabeth E. Joh, DNA Theft: Recognizing the Crime of 
Nonconsensual Genetic Collection and Testing, 91 B.U. L. Rev. 665, 686 
(2011)). 
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surrounding abandoned DNA or the nonconsensual collection and 
testing of genetic material. 99  Additionally, GINA only covers 
asymptomatic individuals as compared to state insurance laws 
which cover symptomatic individuals.100 Moreover, GINA does not 
indicate how DTC genetic tests should be interpreted and 
communicated.101  
Although GINA was enacted in 2008, the EEOC only started 
enforcing the law in 2013.102 However, the EEOC has indicated 
that it plans to enforce GINA against employers, by also settling an 
action against Founders Pavilion, Inc. in early 2014. 103  David 
Lopez, EEOC General Counsel, commented that illegal questions 
will not be tolerated and the “EEOC will be vigilant in ensuring 
that no one is denied employment opportunities on a prohibited 
basis.” 104  Furthermore, the EEOC stated that addressing genetic 
discrimination is one of the six national priorities of the EEOC’s 
Strategic Enforcement Plan.105 
E.  State Laws: Further Complications or a Model for the Future? 
Further complicating matters, various state laws govern the 
status of DTC genetic tests. Twenty-five states,106 including New 
York107 and California,108 have passed statutes or regulations that 
                                                        
99 Id. at 985. 
100 Id. (citing Mark A. Rothstein, GINA's Beauty is Only Skin Deep, GENEWATCH, 
http://www.councilforresponsiblegenetics.org/GeneWatch/GeneWatchPage.aspx
?pageId=184 (last visited Mar. 3, 2013)). 
101 Michelle D. Irick, Age of an Information Revolution: The Direct-to-Consumer 
Genetic Testing Industry and the Need for A Holistic Regulatory Approach, 49 
SAN DIEGO L. REV. 279, 290 (2012).   
102 Founders Pavilion Will Pay $370,000 to Settle EEOC Genetic Information 
Discrimination Lawsuit, U.S. EQUAL OPPORTUNITY EMP’T COMM’N, http:// 
www.eeoc.gov/eeoc/newsroom/release/1-13-14.cfm, (last updated Jan. 13, 2014).  
103 Id. 
104 Id.  
105 Id.  
106  GENETICS & PUB. POLICY CTR., JOHNS HOPKINS UNIV., SURVEY OF 
DIRECT-TO-CONSUMER TESTING STATUTES AND REGULATIONS 1-14 (2007), 
available at http://www.dnapolicy.org/resources/DTCStateLawChart.pdf [hereinafter 
DTC Testing Survey].  
107 See, e.g., N.Y. PUB. HEALTH LAW § 576-b(1) (2002) (requiring that any clinical 
laboratory services be FDA approved); N.Y. PUB. HEALTH LAW § 577 (2011); 
16 N.C. J.L. & TECH. ON. 138, 153 
The Future of Direct-to-Consumer Genetic Testing 
specifically restrict or prohibit DTC genetic testing.109 Accordingly, 
observers fear that “conflicts between the laws of various states, 
and between state and federal law, will increase legal and 
regulatory uncertainty.” 110  The variety in state laws regarding 
genetic testing could serve to fuel further confusion about the 
legality of DTC genetic testing.  
However, some states could serve as models for other states’ 
genetic testing and privacy laws, or as a model for the federal 
government to follow. For example, Alaska’s Genetic Testing 
Statute is more comprehensive than GINA.111 The Alaska statute 
provides a private cause of action against individuals who analyze, 
collect, or retain DNA samples without consent, or individuals that 
release the results of DNA testing.112 The statute requires written 
consent before a person can collect, analyze, retain, or disclose an 
individual’s DNA analysis results.113 
Three other states, Colorado, Florida, and Georgia, also declare 
genetic information to be the private property of the individual to 
which it pertains.114 The Colorado and Georgia statutes are in each 
state’s insurance code, and prohibit the unauthorized testing and 
disclosure, and discrimination of individuals’ DNA for insurance 
                                                                                                                            
10 NYCRR 19.1(j) (2014); 10 NYCRR 58-1.7 (2014); 10 NYCRR § 58-1.8 (2014); 
10 NYCRR § 63.3(e) (2014).  
108 See, e.g., CAL. BUS. & PROF. CODE § 1246.5 (2005) (providing that “[t]he 
tests that may be conducted pursuant to this section are: pregnancy, glucose 
level, cholesterol, occult blood, and any other test for which there is a test for a 
particular analyte approved by the federal Food and Drug Administration for 
sale to the public without a prescription in the form of an over-the-counter test 
kit”). 
109 Alabama, Connecticut, Georgia, Hawaii, Idaho, Kentucky, Michigan, New 
Hampshire, Pennsylvania, Rhode Island, South Carolina, Tennessee, and 
Wyoming specifically prohibit DTC genetic testing; Arizona, California, 
Colorado, Florida, Illinois, Maine, Maryland, Massachusetts, Nevada, New 
Jersey, New York, and Oregon limit DTC genetic testing. DTC Testing Survey, 
supra note 106.  
110 Id.  
111 McFerrin, supra note 98, at 986.  
112 ALASKA STAT. § 18.13.010 (2004). 
113 Id. 
114 SETH AXELRAD, STATES DECLARING GENETIC INFORMATION TO BE PERSONAL 
PROPERTY (2005), available at https://www.aslme.org/dna_04/reports/axelrad4.pdf.  
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purposes.115 The Colorado and Georgia statutes also establish civil 
remedies when insurers engage in unfair practices based on the use 
of DNA.116 Florida and Alaska, on the other hand, both establish 
criminal penalties for misuse of genetic information, 117  which 
might serve to more effectively deter the misappropriation of 
genetic information. These state statutes—all arguably more 
comprehensive than GINA—might not only serve to create a more 
confusing framework for DTC genetic testing companies; rather, 
they may actually serve as a model for future amendments to 
GINA and demonstrate how the EEOC might go about enforcing 
the Act against a DTC genetic testing company under GINA.  
F.  Association for Molecular Pathology v. Myriad Genetics, Inc.: 
Implications to DTC Genetic Testing Companies  
The Supreme Court in Association for Molecular Pathology v. 
Myriad Genetics, Inc.118 removed a potential barrier to large-scale 
DTC genetic testing and genomic sequencing 119  because the 
holding limited the patentability of human genetic material. The 
Supreme Court held that “a naturally occurring DNA segment is a 
product of nature and not patent eligible merely because it has 
been isolated.”120 Moreover, research indicates that limiting genetic 
patents will continue to allow the DTC industry to flourish.121 For 
example, one study found that patents do not appear to be 
                                                        
115 COLO. REV. STAT. § 10-3-1104.7(1)(a) (2009); GA. CODE ANN. § 33-54-1(1) 
(1995). 
116 Axelrad, supra note 114; COLO. REV. STAT. § 10-3-1104.7(11) (2009); GA. 
CODE ANN. § 33-54-8 (1995). 
117 FLA. STAT. § 760.40(2)(a) (2009); ALASKA STAT. § 18.13.010(a)-(b) (2004). 
118 133 S. Ct. 2107 (2013).  
119 Spector-Bagdady & Pike, supra note 14, at 683. 
120 Myriad, 133 S. Ct. at 2111.  
121 Fifty-nine percent of the nation’s basic genetic research is federally funded, 
and therefore patents are not necessary for much of basic research to occur. U.S. 
DEP'T OF HEALTH & HUMAN SERVS., GENE PATENTS AND LICENSING PRACTICES 
AND THEIR IMPACT ON PATIENT ACCESS TO GENETIC TESTS: REPORT OF THE 
SEC'YS ADVISORY COMM. ON GENETICS, HEALTH, & SOC'Y, 2 (Apr. 2010), 
available at http://osp.od.nih.gov/sites/default/files/SACGHS_patents_report_2010.pdf 
(citing Science and Engineering Indicators 2008, NAT’L SCIENCE FOUND., 
http://www.nsf.gov/statistics/seind08/c4/c4h.htm#c4hs (last visited Oct. 20, 2014)).   
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necessary to promote genetic research or to develop genetic tests.122 
The study also indicated that the prospect of patenting a genetic 
research discovery does not play a significant role in motivating 
scientific research.123  
Despite Myriad’s holding that naturally occurring sequences of 
DNA are not patentable,124 other DTC genetic testing companies, 
like 23andMe, Inc. (“23andMe”), currently hold patents related to 
naturally occurring DNA sequences. 125  For example, 23andMe’s 
first patent “Polymorphisms Associated with Parkinson’s Disease,” 
which relates to the discovery of a “variation in the SGK1 gene 
that may be protective against Parkinson’s disease in individuals 
who carry the rare risk-associated LRRK2 G2019S mutation,” seems 
extremely similar to Myriad’s patents of the BRCA1 and BRCA2 
genes that were struck down in Myriad.126 It is theoretically possible 
that 23andMe’s patent could be struck down under a similar theory 
as the Myriad decision came out after the 23andMe patent was 
submitted.  
However, it is unlikely that gene patents will disappear 
post-Myriad. 127  Inventors could utilize trade secret protection, 
although there is a risk another inventor could come up with the 
same invention and the original inventor would lack the legal tools 
to prevent the competitor from profiting from the invention.128 An 
                                                        
122 U.S. DEP'T OF HEALTH & HUMAN SERVS., supra note 121, at 2.  
123 Id.; John M. Golden, Biotechnology, Technology Policy, and Patentability: 
Natural Products and Invention in the American System, 50 EMORY L.J. 101, 
153–54 (2001) (describing that scientists are primarily motivated by idealistic 
desires like “contributing to scientific and technological progress.”).  
124Myriad, 133 S. Ct. 2107, 2115–20 (2013) (holding “[a] naturally occurring 
DNA segment is a product of nature and not patent eligible merely because it 
has been isolated, but cDNA is patent eligible because it is not naturally 
occurring.”). 
125Announcing 23andMe’s First Patent, 23ANDME BLOG (May 28, 2012), 
http://blog.23andme.com/news/announcements/announcing-23andmes-first-patent/.  
126 See id. (referring to the Myriad case ruling in which Myriad’s proposed 
patent was a genetic patent like 23andMe’s). 
127 Jessica L. Marks, et al., Gene Patents Won’t Disappear Post-Myriad, LAW360 
(July 22, 2013), http://www.finnegan.com/resources/articles/articlesdetail.aspx? 
news=b4a7795a-bee4-431a-bab2-47ee02ea5608.  
128 Id.  
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inventor could also attempt to patent isolated nucleic acids rather 
than straightforward, complementary DNA, 129  which the court 
stated is not naturally occurring.130 DTC genetic testing companies 
could continue to “get around” the loophole that naturally 
occurring DNA sequences are not patentable. The Myriad decision 
will continue to affect the DTC industry as various companies are 
allowed to compete with one another to find the best SNP131 sites to 
conduct genetic tests, or as the companies discover new SNP sites 
with the potential for predicting health risks. 
G.  Tompkins v. 23andMe Inc. and Regulatory Repercussions  
A case recently decided in the Northern District of California, 
Tompkins v. 23andMe Inc.,132  involved a class action related to 
defendant 23andMe’s advertising and marketing of its Personal 
Genome Service.133 23andMe’s “FDA takedown” last November 
might have influenced some lawyers to “move in for their cash 
grab,” demonstrating how regulatory decisions can sometimes 
prompt litigation.134 The primary issue between the parties arose 
                                                        
129 Id.  
130 Association for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 
2107, 2107 (2013). 
131  Single Nucleotide Polymorphism or SNP, supra note 11 and 
accompanying text.  
132 5:13-CV-05682-LHK, 2014 WL 2903752, at *1 (N.D. Cal. June 25, 2014).   
133 Id. (“PGS is a service that consists of a DNA saliva collection kit (‘DNA kit’) 
and DNA test results with certain genetic information derived from a consumer's 
saliva sample.”)). 
134 Linda A. Willett, Litigation As an Alternative to Regulation: Problems 
Created by Follow-on Lawsuits with Multiple Outcomes, 18 GEO. J. LEGAL 
ETHICS 1477, 1482 (2005) (“During the past few years, when the FDA has used 
its technical review process to challenge language, photos, or footage in a DTC 
advertisement, a series of private lawsuits, now known as ‘follow-on’ actions, 
has quickly followed. For example, an FDA decision to require withdrawal of 
DTC advertising may be followed by one or more federal and state court 
actions, including class action suits brought under broadly written state 
consumer protection laws by those purporting to represent the citizens of a state. 
Some of these actions are without merit and ultimately result in nothing more 
than a drain on the court system.”); Eric Goldman, 23andMe’s Browsewrap 
Fails, But It’s Post- Purchase Clickthrough Works Anyway—Tompkins v. 23andMe, 
TECH. & MKTG. LAW BLOG (July 2, 2014), http://blog.ericgoldman.org/archives/ 
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out of the arbitration provision in the Terms of Service (section 
28(b)) in the miscellaneous section). 135  The California court 
dismissed the plaintiffs’ class action claims, with 23andMe 
defending an arbitration agreement 136  consumers signed in the 
company’s Terms of Service (“TOS”).137 
The court found that the method of accepting the TOS 
resembled “clickwrap agreements, where an offeree receives an 
opportunity to review terms and conditions and must affirmatively 
                                                                                                                            
2014/07/23andmes-browsewrap-fails-but-its-post-purchase-clickthrough-works-
anyway-tompkins-v-23andme.htm. 
135 Tompkins, 2014 WL 2903752 at *2.  
136 Id. at *1. The arbitration agreement read as follows:  
Applicable law and arbitration. Except for any disputes relating to 
intellectual property rights, obligations, or any infringement claims, any 
disputes with 23andMe arising out of or relating to the Agreement 
(“Disputes”) shall be governed by California law regardless of your country 
of origin or where you access 23andMe, and notwithstanding of any 
conflicts of law principles and the United Nations Convention for the 
International Sale of Goods. Any Disputes shall be resolved by final and 
binding arbitration under the rules and auspices of the American Arbitration 
Association, to be held in San Francisco, California, in English, with a 
written decision stating legal reasoning issued by the arbitrator(s) at either 
party's request, and with arbitration costs and reasonable documented 
attorneys’ costs of both parties to be borne by the party that ultimately 
loses. Either party may obtain injunctive relief (preliminary or permanent) 
and orders to compel arbitration or enforce arbitral awards in any court of 
competent jurisdiction. 
Id. at *2.  
137  During the account creation and registration processes, each named 
Plaintiff clicked a box near a hyperlink to indicate acceptance of the terms of 
service. Id. at *3. 23andMe argued that it was “impossible to register for and 
receive the Service without clicking ‘I ACCEPT’ to the TOS.” Id. at *6 (internal 
quotations omitted). However, the court held that because the only way 
consumers could see the TOS at the time of purchase was to scroll to the bottom 
of the screen, a better practice would be to show or require acknowledgement of 
such terms at the point of sale. Id. at *7. Therefore, the court held that 
23andMe’s TOS would have been ineffective to bind website visitors or 
consumers who purchased a DNA kit without creating an account or registering 
a kit. Id. After the consumers made the purchase, in order to get the results, they 
had to accept the terms of service by clicking a button that appeared near a 
hyperlink of the terms of service. Id. at *8. 
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indicate assent.” 138  However, the court’s reasoning here is 
unsatisfying for two reasons. First, the court ignores the possibility 
of a consumer buying the service for another party (like a minor or 
a friend) and second, the court does not take into account economic 
realities because at that point the consumer cannot receive a full 
refund for their results.139 While the court acknowledges that it is 
possible for a consumer to buy the DNA kit as a gift for someone 
else without creating an account or registering the kit, the court 
moves on without addressing this potential issue. 140  If someone 
were to purchase the kit as a gift for a minor or third party, his or 
her autonomy and privacy concerns might not be addressed. 
The court held that although the terms of service were 
hyperlinked and not on the same screen, the consumers still had 
adequate notice of the terms of service. 141  Although the court 
ultimately upheld the arbitration clause in the agreement and 
dismissed the case without prejudice, 142  the plaintiffs have the 
opportunity to appeal to the Ninth Circuit.143 
While consumer freedom to purchase these products is 
important, agencies like the FTC should work with other 
regulatory bodies (including the FDA, CMS under the CLIA, and 
various state agencies) to draft better procedures to allow 
consumers to fully understand the terms of service. In this case, 
one of the most reputable genetic testing companies arguably 
                                                        
138 Id. at *8. 
139 Goldman, supra note 134.  
140 Tompkins, 2014 WL 2903752 at *3.  
141 Id. at *8. The plaintiffs finally argued that the arbitration agreement in the 
TOS was unconscionable. Id. at *9. The court agreed that the clause was 
procedurally unconscionable because 23andMe’s website provided minimal notice 
of the TOS to consumers. Id. at *14. Additionally, the clause is a standardized 
clause presented as a take-it-or-leave-it agreement, leaving consumers without 
any negotiating power. Id. at *15. The court held that the arbitration agreement 
was not substantively unconscionable. Id. The court held that 23andMe’s 
headquarters as the arbitration forum, a carve out for claims by 23andMe, and 
limitations of legal remedies were “not so unduly harsh or one-sided” to become 
substantively unconscionable. Id. at *16. 
142 Id. at *18.  
143 The case could become “a flagship cyberlaw case.” Goldman, supra note 
134. 
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“obscured the terms of service” in an “unfair way.” 144 Protecting 
consumers from this type of behavior is squarely in the realm of 
the FTC, whose mission is to help protect consumers from 
deceptive and unfair business practices.145 
III.  IMPLICATIONS AND RECOMMENDATIONS 
This part analyzes how a genetic service like Interleukin Inc.’s 
“Inherent Health” might be regulated under the current regulatory 
framework. Each of the various regulatory stakeholders, including 
the FDA, FTC, CLIA, GINA, state genetic testing statutes, and the 
Tompkins decision might become relevant for Interleukin. The 
FTC should enforce regulations against this particular type of 
genetic testing service, informed by heightened CLIA standards.  
A. Inherent Health: Different than 23andMe Under FDA 
Regulation?   
Interleukin Genetics, Inc., a personalized health company, 
introduced Inherent Health™ in 2009. 146  Inerleukin’s Inherent 
Health product includes genetic tests for heart health, weight 
management, nutritional needs, and bone health, among others.147  
Interleukin was among the DTC genetic testing companies that 
received untitled letters 148  in 2010 because the FDA had not 
preapproved Inherent Health. 149  However, since that letter, the 
                                                        
144 Tompkins, 2014 WL 2903752 at *7.  
145 About the FTC, FED. TRADE COMM’N, http://www.ftc.gov/about-ftc (last 
visited Sept. 26, 2014).  
146 About Interleukin Genetics, INTERLEUKIN GENETICS, http://www.ilgenetics.com/ 
content/about-interleukin (last visited Nov. 1, 2014). 
147 Our Genetic Tests, INTERLEUKIN GENETICS, http://www.inherenthealth.com/ 
our-tests.aspx (last visited Nov. 1, 2014).  
148 “Unlike a warning letter, an untitled letter does not include a statement that 
warns the individual or firm that failure to correct the violation may result in 
enforcement action.” U.S. FED. DRUG ADMIN, WARNING AND UNTITLED LETTERS 1 
(2011) available at http://www.fda.gov/downloads/AboutFDA/Transparency/ 
PublicDisclosure/GlossaryofAcronymsandAbbreviations/UCM212064.pdf (last 
visited Nov. 20, 2014).  
149  Letter from James Woods, Deputy Dir., Patient Safety and Product 
Quality, Office of In Vitro Diagnostic Device Evaluation and Safety, Ctr. for 
Devices & Radiological Health, to Lewis H. Bender, CEO, Interleukin Genetics, 
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FDA has not taken further action against the company. The FDA 
probably does not think that Inherent Health posed much of a risk 
to consumers because its genetic test sales have been slipping.150 
For example, in 2013 Inherent Health received a much needed $12 
million injection of capital into its business to “prolong its 
survival.”151 Additionally, Interleukin Genetics never intended to 
sell its brand in national stores like Walgreens like Pathway 
Genomics, nor has it attempted a nationwide televised advertising 
campaign like 23andMe.152 Like all agencies, the FDA has limited 
resources and a finite budget.153 Attempting to enforce regulations 
against every single DTC genetic testing company, however small, 
might not be the best utilization of these resources. 
DTC genetic testing companies like Interleukin should make 
sure to stay in contact with the FDA if they ever receive a warning 
letter. The FDA issued a harsh rebuke to 23andMe because the 
company essentially stopped communicating with the FDA for 
eleven months without completing the certification for its tests and 
planned an aggressive new marketing campaign.154 If 23andMe had 
been more forthcoming with the FDA, the agency might not have 
needed to resort to such harsh measures.  
To be sure, 23andMe arguably offered a better, more reliable 
product than Interleukin Genetics currently does. While Interleukin 
Genetics claims that its Inherent Health product is supported by 
various studies, some argue that companies like Interleukin 
                                                                                                                            
Inc. (July 19, 2010), available at http://www.fda.gov/downloads/MedicalDevices/ 
ProductsandMedicalProcedures/InVitroDiagnostics/UCM219587.pdf. 
150 See Mark Hollmer, Interleukin Genetics Raises $12M in Last-Ditch Save, 
FIERCE MEDICAL DEVICES (May 20, 2013), http://www.fiercemedicaldevices.com/ 
story/interleukin-genetics-raises-12m-last-ditch-save/2013-05-20. 
151 Id.  
152 See supra notes 20–21 and accompanying text. 
153 John Lehmann, Budget Constraints Impacting FDA Strategic Priorities, 
IMARC RESEARCH (July 25, 2014 6:48 AM), http://www.imarcresearch.com/ 
blog/bid/351768/Budget-Constraints-Impacting-FDA-Strategic-Priorities.   
154 See Warning Letter to Wojcicki, supra note 21.   
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Genetics, among others, are bringing the industry down by 
marketing suspect tests.155  
Perhaps Interleukin is the type of company the FDA should be 
regulating. The FDA should worry about the unreliability of the 
“weight loss management product” 156  from Interleukin. 157  DTC 
genetic test critics already fear that science cannot offer certainty 
based on a predictive DTC genetic test. 158  Few resources are 
available to gauge the reliability of the DTC genetic tests. 159 
Furthermore, each test varies according to the specific SNP sites 
analyzed by the test and the capabilities of the individual lab 
performing the test.160 
Studies have questioned the reliability of DTC genetic tests. 
For example, the GAO has conducted a number of investigations 
and other oversight activities related to DTC genetic testing.161 A 
2006 GAO investigation of four companies selling DTC genetic 
tests found that these companies “misled consumers by providing 
test results that were both medically unproven and so ambiguous as 
to be meaningless.”162 In 2008, the Secretary’s Advisory Committee 
on Genetics, Health, and Society discovered that there were 
significant gaps related to the oversight of genetic testing in five 
                                                        
155  See Helen Wallace, Misleading Marketing of Genetic Tests, Will the 
Genome Become the Source of Diagnostic Miracles or Potential Scams? 
COUNCIL FOR RESPONSIBLE GENETICS, http://www.councilforresponsiblegenetics.org/ 
ViewPage.aspx?pageId=88 (last visited Oct. 30, 2014).  
156 Inherent Health advertises weight loss solutions tailored to your genes on 
its main webpage. INHERENT HEALTH, http://www.inherenthealth.com (last 
visited Nov. 1, 2014) [hereinafter inherenthealth.com].  
157  This column reminds readers that while nutrigenomic research is an 
exciting, growing area, diets tailored to your genes are still unproven. Ask the 
Nutritionist, DANA-FARBER CANCER INST., http://www.dana-farber.org/Health-
Library/The-Inherent-Health--Weight-Management-DNA-Test.aspx (last visited 
Nov. 1, 2014). 
158 Jessica D. Gabel, Redeeming the Genetic Groupon: Efficacy, Ethics, and 
Exploitation in Marketing DNA to the Masses, 81 MISS. L.J. 363, 407 (2012). 
159 Id.  
160 Id.  
161 SARATA & JOHNSON, supra note 31, at 17.  
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16 N.C. J.L. & TECH. ON. 138, 162 
The Future of Direct-to-Consumer Genetic Testing 
areas.163 Two years later, the GAO concluded that these tests were 
still “misleading” and “yielded contradictory predictions.”164 Although 
these DTC genetic tests might have some scientific validity, 165 
Inherent Health may be among the genetic testing products with 
unproven and misleading claims. 
B. The FTC: Is Inherent Health “Fit to be Tried?” 
The FTC should regulate companies like Interleukin. 
Interleukin’s Inherent Health tells consumers, “Don’t waste a day 
on the wrong diet! The Weight Management Genetic Test may 
help you lose more weight by properly matching diet and exercise 
to your personal genotypes. No guessing!”166 While Interleukin’s 
Inherent Health may have validity as a CLIA certified testing 
company, this type of blanket statement might simply confuse 
consumers who will believe that a genetic test holds the key to 
their weight loss.167 Because Inherent Health claims to be “CLIA 
certified,” there seems to be a discrepancy between the high 
                                                        
163 These areas include:  
(1) the regulations governing clinical laboratory quality; (2) oversight of the 
clinical validity of genetic tests; (3) the transparency of genetic testing; (4) 
the level of current knowledge about the clinical usefulness of genetic tests; 
and (5) the educational needs of health professionals, the public health 
community, patients and consumers.  
Spector-Bagdady & Pike, supra note 14, at 694 (internal quotations omitted).  
164 U.S. GOV’T ACCOUNTABILITY OFFICE, GAO-10-847T DIRECT-TO-CONSUMER 
GENETIC TESTS: MISLEADING TEST RESULTS ARE FURTHER COMPLICATED BY 
DECEPTIVE MKTG. AND OTHER QUESTIONABLE PRACTICES 4 (2010), available at 
http://www.gao.gov/new.items/d10847t.pdf. “The fact that different companies, 
using the same samples, predict different . . . directions of risk is telling and is 
important. It shows that we are nowhere near really being able to interpret [such 
tests].” Id. at 8.  
165 See Schleckser, supra note 60, at 712 (arguing that the GAO’s conclusions 
might have been “vastly overstated” and the discrepancies in the testing results 
could be accounted for in the diverse standards for SNP site selections between 
different companies). 
166 Take the Guesswork out of Losing Weight, INHERENT HEALTH, http://www. 
inherenthealth.com/our-tests/weight-management.aspx (last visited Sept. 26, 2014) 
[hereinafter Take the Guesswork out of Losing Weight].   
167 Id.  
16 N.C. J.L. & TECH. ON. 138, 163 
The Future of Direct-to-Consumer Genetic Testing 
standards promulgated by other government agencies, and the 
claims this company is making.  
Inherent Health seems to validate concerns that the FTC 
warned against in the L’Oréal matter and the Genelink foru™ 
matter. For example, Inherent Health claims: “Finally—the 
answers you need to get results faster, stay confident and 
motivated, and take control of your weight. Order today!” 168 
Interleukin claims that these conclusions are based on a study, 
partly funded by the company itself.169 However, it is unclear if this 
single study would meet the FTC’s standard that “once companies 
make objective product representations, long standing 
substantiation principles apply.”170 Inherent Health also has a report 
“showing the science behind the test.”171 The “Science Behind the 
Weight Management Genetic Test” demonstrates how the 
company came to the conclusion that five variations in four genes 
impact various pathways that influence body weight and have a 
related risk for obesity.172 Because the company substantiated its 
decision to test those particular genes with multiple scientific 
studies, it is unclear whether this method would be enough to 
survive the FTC’s standard that the product must be “fit to be 
tried.”173 Additionally, “The Science Behind the Weight Management 
Genetic Test” might be too jargon-heavy and inaccessible for the 
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169 Id. In this study:  
240 overweight pre-menopausal women followed either a very-low 
carbohydrate diet, a low-carbohydrate diet, a low-fat high-carbohydrate diet, 
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modification techniques. Participants' DNA were analyzed and the study 
concluded that after 12 months participants who possessed specific genetic 
markers lost, on average, more weight following one type of diet plan than 
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Id.  
170 Fair, supra note 84.  
171 Take the Guesswork out of Losing Weight, supra note 166. 
172  INHERENT HEALTH, THE SCIENCE BEHIND THE WEIGHT MANAGEMENT 
GENETIC TEST, 2 available at http://www.inherenthealth.com/media/4759/ 
wm_scientific%20summary.pdf (last visited Nov. 2, 2014). 
173 Fair, supra note 84.  
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average consumer attempting to verify that the test is scientifically 
accepted. The FTC should make sure that the tests are 
(1) supported by substantial evidence, and (2) consumers can 
understand that these studies are valid.  
C. Make CLIA Certification Meaningful  
Interleukin’s Inherent Health also demonstrates that CLIA 
should be doing more to regulate these DTC genetic testing 
companies. The “CLIA certified”174 label on the Inherent Health 
product might convince consumers that the product is reliable. The 
Interleukin Genetics lab in Waltham, Massachusetts has achieved a 
CLIA “Certificate of Compliance.” 175  This CLIA certification 
seems to be in contradiction with the FDA’s 2010 letter expressing 
concern about Interleukin’s DTC genetic testing and the FTC’s 
stance on DTC genetic testing. A better practice would be to make 
sure that a company in compliance with one of the federal 
regulatory mechanisms is in compliance with all of them; it is 
misleading to consumers to say that it is certified by one federal 
regulatory mechanism but not another.  
D. GINA and State Genetic Testing Statutes: A Privacy Paradigm  
DTC genetic testing opponents are concerned about a 
consumer’s privacy after these consumers purchase the Inherent 
Health product. 176  Specifically, critics are concerned with what 
                                                        
174 There are five different CLIA Certificates including: Certificate of Waiver; 
a certificate for microscopy procedures; a certificate of registration for midlevel 
or high complexity tests; a certificate of compliance after inspection; and a 
certificate of accreditation on the basis of an accreditation organization approved 
by the Healthcare Financing Administration. CTRS. FOR MEDICARE AND 
MEDICAID SERVS., TYPES OF CLIA CERTIFICATES 1 (2003), available at 
https://www.cms.gov/Regulations-and-Guidance/Legislation/CLIA/downloads/ 
TYPES_OF_CLIA_CERTIFICATES.pdf (last visited Nov. 11, 2014).  
175 22D1038543 CLIA Number - Interleukin Genetics, Inc., HEALTH PROVIDERS 
DATA http://healthprovidersdata.com/hipaa/codes/CLIA_22D1038543.aspx (last 
visited Nov. 11, 2014).  
176 See Lauren B. Solberg, Over the Counter but Under the Radar: Direct-to-
Consumer Genetics Tests and FDA Regulation of Medical Devices, 11 VAND. J. 
ENT. & TECH. L. 711, 721 (2009) (“Although genetic testing services may 
inform consumers that their genetic material or information may be sold to third 
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should and will happen to genetic testing information from 
minors. 177  Despite critics’ fears, companies like Interleukin 
Genetics do expressly address the issues associated with genetic 
testing information from minors. For example, Interleukin’s 
Inherent Health privacy policy specifically indicates, “Our Website 
is not intended for, or designed to attract, children under the age of 
13.”178  
The Interleukin privacy policy also explains that the company 
utilizes several different procedures to protect a client’s personal 
information, including using assigned usernames and passwords, 
anonymous barcodes for DNA, server firewalls, and an encrypted 
website.179 Interleukin also specifically acknowledges GINA under 
a section entitled “Federal Laws Protecting You.”180 The company 
explains that a consumer is not required to share the genetic 
information with an insurer or an employer.181 The company also 
explains that there are “state laws that prevent insurers, employers, 
and others from using genetic tests for discriminatory purposes,” 
depending on the state.182 While consumers would have to read the 
privacy policy to find the information that could potentially 
address their privacy concerns, the policy seems relatively 
comprehensive to help educate consumers about their privacy 
rights.  
 
 
 
                                                                                                                            
parties and used for research purposes, questions arise as to whether individuals 
are aware of this practice and understand he ramifications of consenting to this 
use of their genetic material.”).  
177 See Pascal Borry et al., Is There A Right Time to Know? The Right Not to 
Know and Genetic Testing in Children, 42 J.L. MED. & ETHICS 19, 20 (2014). 
178 Privacy Policy, INHERENT HEALTH, http://www.inherenthealth.com/privacy- 
policy.aspx (last updated June 15, 2009).  
179 Id.  
180 Id.  
181 Id. 
182 Id.  
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E. Interleukin Genetics, Tompkins, and Consumer Autonomy 
Concerns related to DTC Genetic Testing  
Like in 23andMe v. Tompkins, Interleukin’s terms of use might 
be obscured in an unfair way. 183 In order to sign up for a new 
account on Interleukin’s website, one must create a user name, 
password, and fill out your email with a security question and 
security answer.184 Next, a consumer must certify that they are at 
least eighteen years old and they agree to comply with 
Inherenthealth.com’s terms of use. 185  The terms of use are 
hyperlinked to another page. 186  Interleukin does not require a 
consumer to acknowledge the terms of service after creating an 
account in order to purchase the product. This formulation seems 
similar to 23andMe’s former practice, which might give rise to 
similar criticisms. 187  Theoretically, a third party could use the 
account to purchase the product without ever seeing the terms of 
service. A better practice would be for a consumer to acknowledge 
the terms again at the time of purchasing the product.188  
The terms of use also indicate service limitations, including a 
recommendation that consumers discuss any health-related 
findings with a physician or health care professional regarding the 
diagnosis, prevention, or treatment of a condition. 189  Interleukin 
also does not warrant that the information on the website, 
including information about the products actually offered, is 
completely accurate and current, including information about the 
products actually offered. 190  These terms of use highlight the 
arguments in favor of a role for a learned intermediary, such as a 
physician, in the interpretation of the genetic test results.  
                                                        
183 See Tompkins v. 23andMe Inc., 5:14-CV-00429-LHK, 2014 WL 2903752 
at *1 (N.D. Cal. June 25, 2014). 
184 Sign up for a new Account, INHERENT HEALTH, http://www.inherenthealth.com/ 
store/register.aspx (last visited Nov. 2 2014). 
185 Id.  
186 Terms of Use, INHERENT HEALTH (June 5, 2009), http://www.inherenthealth.com/ 
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Without the help of physician interpretation, consumers who 
receive their genetic tests from a company like Interleukin could 
misunderstand the results—a misunderstanding that could lead to 
severe psychological trauma.191 It could be traumatic to learn that a 
DTC genetic test predicts an increased risk for diseases such as 
Alzheimer’s or Huntington’s, which are incurable or have limited 
treatment options. 192  While Interleukin is selling health-related 
genetic tests, these tests are related to weight management and 
nutrition, and none purport to predict disease risks.193 These types 
of tests seem more analogous to various weight loss apps like 
“MyFitnessPal,” where users can track their weight, calorie intake, 
and exercise habits. 194  While users could and perhaps should 
consult with physicians regarding their weight, exercise, and other 
habits, ultimately the decisions to exercise or eat certain foods 
should be left to the individual.  
Furthermore, genetic counseling for consumers who wish to 
seek advice to better inform their decisions may be prohibitively 
expensive.195 For example, 23andMe offered genetic counseling for 
a price range of $99 to speak to a genetic counselor, and up to 
$250 to have “comprehensive” clinical genetic counseling. 196 
                                                        
191 See Solberg, supra note 176, at 720; see also Gabrielle Kohlmeier, The 
Risky Business of Lifestyle Genetic Testing: Protecting Against Harmful 
Disclosure of Genetic Information, 2007 UCLA J.L. & TECH. 5, 5 n.75 (2007) 
(explaining that many individuals who learn that they have Huntington’s disease 
allele, suffer from depression and many have committed suicide). But see 
Shweta U. Dhar et al., Enhancing Exposure to Genetics and Genomics Through 
an Innovative Medical School Curriculum, 14 GENETICS MED. 163, 163 (2012) 
(explaining that many doctors are not prepared to assist their patients in 
interpreting results); Schleckser, supra note 60, at 712 (explaining that involving 
physicians in the genetic test interpretation process could exacerbate privacy 
concerns). 
192 Solberg, supra note 176, at 720. 
193 See inherenthealth.com, supra note 156.  
194 Parmy Olson, MyFitnessPal Starts Tracking Steps to Grow The World’s Largest 
Nutrition Database, FORBES (May 1, 2014, 10:00 AM) http://www.forbes.com/ 
sites/parmyolson/2014/05/01/myfitnesspal-starts-tracking-steps-to-grow-the-worlds- 
largest-nutrition-database/. 
195 Id.  
196 Gabel, supra note 158, at 407 (explaining that 23andMe collaborated with 
a third party provider to give consumers optional access to genetic counselors).  
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Geneticists and medical professionals maintain that this limited 
counseling available from the companies is inadequate because the 
company providing the counseling has an interest in selling more 
tests.197 
In addition, while consumers might misunderstand the results 
of their genetic tests from companies like Interleukin; patients 
might also misunderstand any type of diagnosis from their doctor, 
or the results from any other medical test. While there is always a 
chance of miscommunication, the vast majority of consumers are 
interpreting their results correctly.198 Evidence also conflicts with 
critics’ fears that consumers who learn they have an increased risk 
for certain diseases might take extreme actions. 199  Many DTC 
genetic test consumers understand there are many variables 
influencing the risk of disease.200  
Based on this information, it is clear that many consumers can 
understand the results of the genetic test itself, but that it might be 
best to involve a physician to ensure that consumers are 
interpreting their results correctly and take the best course of action 
regarding their results. Involvement of medical professionals could 
impede the autonomy some patients might value from DTC genetic 
testing,201 but some individuals are using these DTC genetic tests to 
make a significant medical decision based on their health risks for 
                                                        
197 Jennifer A. Gniady, Regulating Direct-to-Consumer Genetic Testing: Protecting 
the Consumer Without Quashing A Medical Revolution, 76 FORDHAM L. REV. 
2429, 2450 (2008).  
198  For example, in one survey, between 91% and 95% of participants 
interpreted straightforward messages correctly, demonstrating that most 
consumers understand how to interpret increased risk, decreased risk, or equal 
risk correctly. Robert C. Green & Nita A. Farahany, The FDA is Overcautious 
on Consumer Genomics, 505 NATURE 286, 287 (2014). In a different study, 90% 
of participants answered questions correctly about their results. Schleckser, 
supra note 60, at 719. 
199 Green & Farahany, supra note 198, at 287.  
200  Colleen M. McBride et al., Consumers’ Views of Direct-to-Consumer 
Genetic Information, 11 ANN. REV. GENOMICS HUM. GENETICS 427, 434 (2010) 
(citing seven scientific studies supporting this premise).   
201  Gabel, supra note 158, at 400 (explaining that DTC genetic testing 
companies focused on recreational purposes in the industry’s infancy). 
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serious conditions like Huntington’s or Alzheimer’s.202 Therefore, 
physician involvement might outweigh autonomy concerns when 
interpreting results for incurable diseases, but not for companies 
like Interleukin that provide weight-loss plans. 
G. Bringing the Regulatory Framework Together for Interleukin 
Genetics  
Perhaps Interleukin Genetics will stay off the FDA’s radar 
because its consumer base is relatively small in comparison to 
other DTC genetic testing companies. However, if Interleukin 
makes major marketing plans or stops communicating with the 
FDA regarding any key changes, the company should expect to be 
sanctioned similarly to 23andMe. The FDA has indicated its 
displeasure at being kept out of the loop.203 Silicon Valley start-ups 
and genetic researchers might not be as concerned with regulatory 
agencies in Washington when their goals include innovating 
toward the future. However, the agency’s decision to curtail 
23andMe’s health-related Personal Genome Service has sent 
shockwaves through the industry, and other companies offering 
health-related products should pay attention. Some speculate 
23andMe’s recent negative experience is why Apple’s new 
“HealthKit” update was released without much fanfare.204 
The FTC seems to be the natural choice to enforce regulations 
against Interleukin and expose whether the company is misleading 
consumers or making unsubstantiated claims about the Inherent 
Health product. The FTC’s recent enforcements against Genelink 
and L’Oreal indicate that the agency is willing to put companies to 
the test to make sure their products are “fit to be tried.”  
                                                        
202 Deepthy Kishore, Test at Your Own Risk: Your Genetic Report Card and 
the Direct-to-Consumer Duty to Secure Informed Consent, 59 EMORY L.J. 1553, 
1567 (2010) (explaining that consumer may make decisions “like whether to 
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certain cancers”). 
203 See Warning Letter to Wojcicki, supra note 21.   
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In order to make sure that Interleukin is consistently able to 
make health-related claims credibly, CLIA certification needs to 
mean something more. A CLIA certification should indicate that 
laboratories are clinically and analytically valid to be useful to 
potential consumers. Systematic gaps in the oversight of these 
laboratories need to be addressed. If a laboratory is CLIA certified, 
the FDA and the FTC should not indicate that the genetic tests are 
unreliable. 
State genetic testing statutes and GINA should serve to 
ameliorate consumer concerns about privacy. The Tompkins v. 
23andMe decision should inform Interleukin and other DTC 
genetic testing companies about the appropriate ways to formulate 
their terms of use. The Myriad decision should remind genetic 
testing companies and Interleukin that patenting a natural DNA 
sequence will not withstand a reviewing court’s scrutiny. Genetic 
testing companies should be regulated in a way that allows for 
innovation. 
IV.  CONCLUSION 
Despite the obvious limitations and shortcomings of the current 
DTC testing market, the current regulatory framework might 
inhibit future innovation rather than save consumers from 
themselves. For example, 23andMe’s fight to go forward with 
premarket approval for one test demonstrates how the company’s 
battle with the FDA will be long and time-consuming.205 In the 
meantime, 23andMe is looking for new markets abroad, where 
standards are less restrictive and the consumers will not be bound 
by the FDA’s ruling.206 The FDA’s attempts to slow the growth of 
the industry may prove fruitless due to other open-data source 
                                                        
205 See Robert Hof, Seven Months After FDA Slapdown, 23andMe Returns 
with New Health Report Submission, FORBES (June 20, 2014, 12:04 PM), 
http://www.forbes.com/sites/roberthof/2014/06/20/seven-months-after-fda-slapdown- 
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206  Christina Farr, Gene Startup 23andMe Casts Eyes Abroad After U.S. 
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desktop applications 207  and the growth of other internationally 
based genetic sequencing firms.208 While the FDA’s concerns are 
not completely unfounded, regulators might not understand the 
true nature of the risk involved in receiving genetic information 
from these DTC genetic testing services.209 
Between the FDA banning all health-related genetic tests by 
23andMe and Interleukin’s unfettered offering of Inherent Health 
lies a compromise. First, while the FDA should certainly play a 
role in the regulation of these genetic tests, it should allow for an 
acceleration of genetic test approval after 23andMe’s pending 
initial approval of the Bloom syndrome test. Second, the FTC 
should step in to help make sure that consumers are not misled into 
purchasing products with unfounded health-related claims and are 
able to read and understand the terms of service of these products. 
Third, CMS under CLIA should ensure that Interleukin’s Inherent 
Health tests are analytically valid, but that they also have clinical 
validity and utility. Fourth, legislators should clarify what the role 
of GINA should be for DTC genetic testing companies. While 
there is still room for state regulation, in an increasingly 
international platform for these tests, it might be prudent for the 
federal government to take a larger role in the regulation of DTC 
tests. Finally, while isolated naturally occurring DNA sequences 
may no longer be patentable, there remain significant opportunities 
for DTC genetic testing companies to patent their discoveries. 
These different regulatory mechanisms need to coordinate together 
to help this burgeoning industry grow in a responsible, sustainable 
way. 
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